Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 02, 2026
Why Is Arteris (AIP) Stock Down -21.21% Today?

Why Is Arteris (AIP) Stock Down -21.21% Today?

Key Takeaways

  • AIP shares have plunged approximately 21.21% in today's session, extending a brutal two-day sell-off that has erased roughly 29% of the stock's value since the July 1 close.
  • The primary catalyst appears to be a confluence of aggressive insider selling, the upcoming departure of the company's CFO, and mounting valuation concerns following a parabolic rally that had pushed the stock up more than 350% over the past year.
  • Secondary drivers include a broader rotation out of high-beta, unprofitable semiconductor names and a technical breakdown below key moving averages.
  • The semiconductor IP provider's stock had been one of the standout performers in the small-cap technology space, making it particularly vulnerable to profit-taking.
  • Traders are now watching for any stabilization near the $30 level and whether the company's upcoming Q2 earnings report in August can restore confidence.

Opening Summary

Arteris, Inc. (AIP), a Campbell, California-based provider of network-on-chip interconnect intellectual property and system-on-chip integration automation software, is experiencing one of its most severe single-day declines in recent memory. As of mid-afternoon trading on Thursday, shares of AIP were down approximately 21.21%, changing hands around $34.52 after closing the previous session at $43.81. The sell-off, which began on Wednesday with a 9.84% drop, has intensified today on heavy volume, reflecting a sharp reversal in market sentiment toward the high-flying semiconductor IP name.

Insider Selling Wave and CFO Departure Weigh on Sentiment

One of the most significant factors undermining investor confidence in AIP has been a sustained wave of insider selling over the past three months. According to regulatory filings, company insiders have sold approximately $35.9 million worth of shares during this period, with zero insider purchases recorded. Notable transactions include CFO Nicholas Hawkins selling $7.38 million worth of stock in mid-May, CEO K. Charles Janac offloading shares in April and June, COO Laurent Moll selling nearly $1.7 million in stock in mid-June, and multiple directors reducing their positions. The complete absence of insider buying amid the selling spree has raised red flags among investors, particularly given the stock's meteoric rise.

Compounding these concerns, the company announced on May 12 that CFO Nicholas Hawkins will retire effective August 31, 2026, citing a family illness. While the departure was characterized as amicable and Hawkins will remain as an advisor during the transition, the loss of a key financial executive during a period of rapid growth and ongoing unprofitability has added an element of uncertainty. The board has initiated a search for a new CFO, but the leadership vacuum is being felt acutely as the stock re-prices lower.

Valuation Concerns After a Parabolic Rally

Even with today's dramatic decline, AIP shares are still up more than 150% year-to-date, having surged from around $8.00 at their 52-week low to a recent high of $44.94. The rally was fueled by enthusiasm for the company's positioning in AI-driven chip design, a string of positive analyst revisions following a strong Q1 2026 earnings report, and growing traction with hyperscaler and automotive customers. However, the stock's price-to-sales ratio had ballooned to over 22, far exceeding the semiconductor industry median of approximately 5.3, making it one of the most richly valued names in the sector despite the company's lack of GAAP profitability.

With a GF Score of 59 out of 100 and a profitability rank of just 2 out of 10, the fundamental picture has struggled to justify the elevated valuation. As the broader market has shown signs of rotation away from speculative growth names, AIP has become a prime target for profit-taking.

Technical Breakdown and Volume Surge

Today's price action has been accompanied by a massive surge in trading volume, with more than 1.3 million shares changing hands by early afternoon—well above the 10-day average of approximately 1.0 million shares. The stock has sliced through several key technical levels, including its 50-day moving average, which had been providing support during the recent uptrend. The breach of these levels has likely triggered additional selling from momentum-focused traders and algorithmic strategies, accelerating the intraday decline. The stock's high beta of approximately 1.98 has amplified the move relative to the broader market.

Market Context and Trading Activity

The sell-off in AIP is occurring against a backdrop of mixed trading in the broader semiconductor sector. While larger-cap names such as NVDA and AVGO have held relatively steady, smaller, unprofitable semiconductor IP and design companies have faced heightened selling pressure. The SMH semiconductor ETF was modestly lower on the session, but the magnitude of AIP's decline far exceeds the sector average, indicating that company-specific factors are the primary drivers. The stock's elevated short interest may also be contributing to the volatility, as the rapid decline could be forcing margin calls or triggering stop-loss orders among leveraged longs.

Trending AI Robots

In volatile market environments like the one impacting AIP today, traders often turn to automated strategies to navigate sharp price swings. Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers across various strategies, timeframes, and performance metrics, the platform highlights only those algorithms that are currently excelling. Whether you are looking for short-term momentum plays or longer-term value strategies, exploring the Trending AI Robots section can help you identify data-driven approaches to today's fast-moving markets.

What Comes Next for AIP

Looking ahead, the immediate focus for AIP investors will be on whether the stock can find a floor after this punishing two-day rout. The company's next quarterly earnings report, expected around August 11, 2026, will be a critical event. Analysts are currently projecting Q2 revenue of approximately $24 million and a non-GAAP operating loss of $2 million to $3 million, in line with the company's own guidance. Any deviation from these expectations could trigger further volatility.

Additionally, the search for a new CFO will be closely watched. The appointment of a well-regarded successor could help stabilize sentiment, while a prolonged vacancy may keep a cloud over the stock. Broader sector dynamics, including demand for AI-related semiconductor IP and the pace of chiplet adoption, will also play a role in shaping the long-term narrative. For now, the stock's dramatic re-pricing serves as a reminder of the risks inherent in high-momentum, high-valuation names, particularly when insider activity and leadership changes raise questions about the sustainability of the rally.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AIP

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


AIP in +4.32% Uptrend, rising for three consecutive days on October 02, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AIP advanced for three days, in 243 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AIP's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for AIP just turned positive on September 08, 2026. Looking at past instances where AIP's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 63 cases where AIP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AIP as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

AIP broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AIP entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AIP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AIP's P/B Ratio (16.779) is slightly higher than the industry average of (7.902). P/E Ratio (0.000) is within average values for comparable stocks, (163.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.705). Dividend Yield (0.000) settles around the average of (0.007) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (45.163).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock worse than average.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Broadcom Inc. (NASDAQ:AVGO), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), QUALCOMM (NASDAQ:QCOM), Analog Devices (NASDAQ:ADI).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 216.18B. The market cap for tickers in the group ranges from 86.8K to 5.53T. NVDA holds the highest valuation in this group at 5.53T. The lowest valued company is STRB at 86.8K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 5%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 51%. WOLF experienced the highest price growth at 22%, while MOBX experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -0% and the average quarterly volume growth was -57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 51
Price Growth Rating: 41
SMR Rating: 72
Profit Risk Rating: 71
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
AIP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Semiconductors

Industry
N/A
Address
900 East Hamilton Avenue
Phone
+1 408 470-7300
Employees
299
Web
https://www.arteris.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.